Sanofi, GlaxoSmithKline jump back into the PhIII race for a Covid vaccine — as the winners congregate behind the finish line
Sanofi got out early in the race to develop a vaccine using more of a traditional approach, then derailed late last year as their candidate failed to work in older people. Now, after likely missing the bus for the bulk of the world’s affluent nations, they’re back from that embarrassing collapse with a second attempt using GSK’s adjuvant that may get them back on track — with a potential Q4 launch that the rest of the world will be paying close attention to.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.